Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

Clinical trial NCT01208051 · COMPLETED

Trial details

NCT number: NCT01208051
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Refractory Differentiated Thyroid Gland Carcinoma Refractory Thyroid Gland Follicular Carcinoma Refractory Thyroid Gland Hurthle Cell Carcinoma Refractory Thyroid Gland Papillary Carcinoma Unresectable Thyroid Gland Carcinoma

Start date: 2010-09-09
Primary completion: 2020-02-01
Enrollment: 127

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.